Patient recruitment is “not just about finding ways to talk to the patients already in our database,” thought leader warns.
Recent FDA guidance on diversity in clinical trials is “a step in the right direction,” but “doesn’t go far enough,” expert says.
“There’s lots you can do even before the clinical trial starts to be more inclusive of the LGBTQ+ population.”
Sponsors who turn to the same study sites over and over again are missing out on others with sturdy local roots in underserved communities, expert says.
When the hopes raised by participation in clinical trials threaten to be dashed by economic and logistical realities, one foundation has been a “godsend” for many cancer patients.
